Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
A case is reported of a poorly differentiated hepatocellular carcinoma that occurred in a 65-year-old patient who was on hormonotherapy for prostatic adenocarcinoma. The diagnosis of hepatocellular carcinoma was made 3 months after the initiation of a hormonal treatment with cyproterone acetate (for 1 month) and an LH-RH agonist. A cause and effect relationship between steroid hormones and hepatocellular carcinoma has been advocated in the literature. The occurrence of hepatic malignancy after a short hormonal therapy makes our case very unusual.
Kattan
J
J
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
Spatz
A
A
Culine
S
S
Terrier-Lacombe
M J
MJ
Elias
D
D
Droz
J P
JP
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced*; D017373:Cyproterone Acetate / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D017329:Triptorelin Pamoate / Q000009:adverse effects
D017329:Triptorelin Pamoate; D017373:Cyproterone Acetate